Novartis bags elusive US approval for cholesterol drug incli...

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year.

AZ and Ionis' PCSK9 cholesterol drug will not move to phase ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.

Verve starts trials of cholesterol drug in test of base edit...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot t

Amgen pulls higher-priced Repatha to try to lift sales

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

Cancer update buoys Amgen despite Q2 sales fall